Press Releases

September 19, 2022

Naveris, Inc. Raises $51 Million to Advance Commercialization of NavDx

NATICK, Mass.–(BUSINESS WIRE)–Naveris, Inc., a commercial-stage life sciences company dedicated to improving patient care through earlier detection of viral-driven cancers, today announced a $33.4 million expansion of its Series A financing, bringing the total investment in Naveris to $51 million.

June 3, 2022

Naveris Announces Abstract Accepted for Presentation at the 2022 American Society for Clinical Oncology (ASCO) Annual Meeting

NATICK, Mass.–(BUSINESS WIRE)–Naveris, Inc. announces the presentation of an abstract related to its flagship diagnostic test for TTMV-HPV DNA (NavDx®) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place from June 3 through June 7, 2022 in Chicago and virtually.

February 24, 2022

Naveris’ Head and Neck Cancer Recurrence Detection Study Selected for Presentation at ASTRO 2022 Plenary Session

NATICK, Mass.–(BUSINESS WIRE)–Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the presentation of significant new data at the plenary session of the ASTRO 2022 Multidisciplinary Head and Neck Cancers Symposium supporting the clinical value of its flagship diagnostic test, NavDx®.

June 2, 2021

New Saliva Test Detects Head and Neck Cancer

Waltham, MA— A new clinically-validated saliva test has been shown to detect HPV-associated head and neck cancer with high accuracy, a first-of-its-kind study result. Researchers at Washington University School of Medicine in St. Louis used the Naveris, Inc. test to analyze saliva for sequences of the human papilloma virus (HPV) genome that are specific for HPV DNA released from malignant tumors.

February 05, 2020

Blood Test Accurately Identifies HPV-related Head and Neck Cancer Recurrence; Prospective Clinical Study Published in Journal of Clinical Oncology

WALTHAM, Mass.–(BUSINESS WIRE)–A novel blood test can detect recurrent Human Papilloma Virus (HPV)-related head and neck (oropharyngeal) cancers, according to a study published online in the Journal of Clinical Oncology by researchers at the University of North Carolina School of Medicine.

December 15, 2020

Naveris, Inc. Raises $19 Million in Financing to Advance and Commercialize Blood Tests for Early Detection of HPV and Other Viral-Related Cancers

NATICK, Mass.–(BUSINESS WIRE)–Naveris, a healthcare company dedicated to improving patient care through early detection of virus-related cancers, today announced the close of its expanded Series A financing, bringing the total raised to over $19 million since the company’s inception. Gurnet Point Capital (GPC), a private investment fund focused in the healthcare and life sciences sector, led the financing round.

October 22, 2018

Naveris Congratulates Scientific Advisors Bhisham Chera and Gaorav Gupta on Presentation of Clinical Data at the 2018 ASTRO Annual Meeting

WALTHAM, Mass., Oct. 22, 2018 /PRNewswire/ — Naveris, Inc., a private biotechnology company developing blood tests for early cancer detection, congratulates Bhisham Chera, M.D. and Gaorav Gupta, M.D., Ph.D., scientific advisors and co-chairs of its Scientific Advisory Board, and announces the presentation of clinical trial data at the American Society for Radiation Oncology annual meeting being held October 21 to October 24, 2018, in San Antonio, TX.